Queen’s University Belfast researchers, in partnership with the Belfast Trust, are leading a clinical trial evaluating a new combination of two radiotherapy treatments in men with advanced prostate cancer (PC), where the cancer has spread to the bones.
The ADRRAD trial, for Androgen Deprivation Therapy, Pelvic Radiotherapy and Radium-223 for presentation T1-4 N/1 M1B adenocarcinoma of prostate, has already started at the Northern Ireland Cancer Centre, Belfast, and is funded by Friends of the Cancer Centre and Bayer Pharmaceuticals.
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?